NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01528618,Effect and Safety Study of GP/FP Regimens in Advanced Nasopharyngeal Carcinoma,https://clinicaltrials.gov/study/NCT01528618,,COMPLETED,"The present study will be a randomized, control, multicenter phase III study of recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC) treated with Gemcitabine (Gemzar, Lilly) and cisplatin regimen (GP) or 5-Fluorouracil plus cisplatin regimen (FP). The population consists of recurrent or metastatic nasopharyngeal carcinoma (NPC) that failed the radical radiotherapy or chemotherapy-na√Øve advanced NPC (stage IV). The effectiveness and side effects will be evaluated according to Standard WHO response criteria and NCI-CTC AE V3.0.",NO,Nasopharyngeal Neoplasms,DRUG: gemcitabine and cisplatin|DRUG: 5-Fluorouracil and cisplatin,"Progression free survival (PFS) assessed by independent image committee and the investigators, 36 months","Overall survival (OS), 36 months|Objective response rate (ORR), 36 months|Number of Participants with Adverse Events, 36 months",,Sun Yat-sen University,,ALL,"ADULT, OLDER_ADULT",PHASE3,362,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,GEM20110714,2012-02-21,2016-04-10,2020-12-20,2012-02-08,,2021-10-04,"Department of Medical Oncology,Cancer Center of Sun Yat-Sen University, Guangzhou, Guangdong, 510060, China",
